BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 36252775)

  • 21. Chronic exposure of human glioblastoma tumors to low concentrations of a pesticide mixture induced multidrug resistance against chemotherapy agents.
    Doğanlar O; Doğanlar ZB; Kurtdere AK; Chasan T; Ok ES
    Ecotoxicol Environ Saf; 2020 Oct; 202():110940. PubMed ID: 32800223
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Resistance to daunorubicin, imatinib, or nilotinib depends on expression levels of ABCB1 and ABCG2 in human leukemia cells.
    Kosztyu P; Bukvova R; Dolezel P; Mlejnek P
    Chem Biol Interact; 2014 Aug; 219():203-10. PubMed ID: 24954033
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Coexpression of ABCB1 and ABCG2 in a Cell Line Model Reveals Both Independent and Additive Transporter Function.
    Robinson AN; Tebase BG; Francone SC; Huff LM; Kozlowski H; Cossari D; Lee JM; Esposito D; Robey RW; Gottesman MM
    Drug Metab Dispos; 2019 Jul; 47(7):715-723. PubMed ID: 31048454
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ABCB1 and ABCG2 Regulation at the Blood-Brain Barrier: Potential New Targets to Improve Brain Drug Delivery.
    Schulz JA; Hartz AMS; Bauer B
    Pharmacol Rev; 2023 Sep; 75(5):815-853. PubMed ID: 36973040
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis.
    Cotte S; von Ahsen N; Kruse N; Huber B; Winkelmann A; Zettl UK; Starck M; König N; Tellez N; Dörr J; Paul F; Zipp F; Lühder F; Koepsell H; Pannek H; Montalban X; Gold R; Chan A
    Brain; 2009 Sep; 132(Pt 9):2517-30. PubMed ID: 19605531
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Olomoucine II, but not purvalanol A, is transported by breast cancer resistance protein (ABCG2) and P-glycoprotein (ABCB1).
    Hofman J; Kučera R; Cihalova D; Klimes J; Ceckova M; Staud F
    PLoS One; 2013; 8(10):e75520. PubMed ID: 24116053
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells.
    Ji N; Yang Y; Cai CY; Lei ZN; Wang JQ; Gupta P; Shukla S; Ambudkar SV; Kong D; Chen ZS
    Cancer Lett; 2019 Jan; 440-441():82-93. PubMed ID: 30315846
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of ABCB1, ABCC1 and 3 and ABCG2 in glioblastoma and their relevance in relation to clinical survival surrogates.
    Roy LO; Lemelin M; Blanchette M; Poirier MB; Aldakhil S; Fortin D
    J Neurooncol; 2022 Dec; 160(3):601-609. PubMed ID: 36342588
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PET-CT imaging with [(18)F]-gefitinib to measure Abcb1a/1b (P-gp) and Abcg2 (Bcrp1) mediated drug-drug interactions at the murine blood-brain barrier.
    Vlaming ML; Läppchen T; Jansen HT; Kivits S; van Driel A; van de Steeg E; van der Hoorn JW; Sio CF; Steinbach OC; DeGroot J
    Nucl Med Biol; 2015 Nov; 42(11):833-41. PubMed ID: 26264927
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The FLT3 and PDGFR inhibitor crenolanib is a substrate of the multidrug resistance protein ABCB1 but does not inhibit transport function at pharmacologically relevant concentrations.
    Mathias TJ; Natarajan K; Shukla S; Doshi KA; Singh ZN; Ambudkar SV; Baer MR
    Invest New Drugs; 2015 Apr; 33(2):300-9. PubMed ID: 25597754
    [TBL] [Abstract][Full Text] [Related]  

  • 31. LRIG1, human EGFR inhibitor, reverses multidrug resistance through modulation of ABCB1 and ABCG2.
    Liu B; Guo Z; Dong H; Daofeng T; Cai Q; Ji B; Zhang S; Wu L; Wang J; Wang L; Zhu X; Liu Y; Chen Q
    Brain Res; 2015 Jun; 1611():93-100. PubMed ID: 25801120
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib.
    Dohse M; Scharenberg C; Shukla S; Robey RW; Volkmann T; Deeken JF; Brendel C; Ambudkar SV; Neubauer A; Bates SE
    Drug Metab Dispos; 2010 Aug; 38(8):1371-80. PubMed ID: 20423956
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Karanjin interferes with ABCB1, ABCC1, and ABCG2.
    Michaelis M; Rothweiler F; Nerreter T; Sharifi M; Ghafourian T; Cinatl J
    J Pharm Pharm Sci; 2014; 17(1):92-105. PubMed ID: 24735762
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SIS3, a specific inhibitor of Smad3 reverses ABCB1- and ABCG2-mediated multidrug resistance in cancer cell lines.
    Wu CP; Murakami M; Hsiao SH; Liu TC; Yeh N; Li YQ; Hung TH; Wu YS; Ambudkar SV
    Cancer Lett; 2018 Oct; 433():259-272. PubMed ID: 30026175
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Novel Synthetic Dihydroindeno[1,2-b] Indole Derivative (LS-2-3j) Reverses ABCB1- and ABCG2-Mediated Multidrug Resistance in Cancer Cells.
    Guo C; Liu F; Qi J; Ma J; Lin S; Zhang C; Zhang Q; Zhang H; Lu R; Li X
    Molecules; 2018 Dec; 23(12):. PubMed ID: 30544754
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of ABC transporters is an unfavorable prognostic factor in laryngeal squamous cell carcinoma.
    Shen B; Li D; Dong P; Gao S
    Ann Otol Rhinol Laryngol; 2011 Dec; 120(12):820-7. PubMed ID: 22279954
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quantitative and Mechanistic Understanding of AZD1775 Penetration across Human Blood-Brain Barrier in Glioblastoma Patients Using an IVIVE-PBPK Modeling Approach.
    Li J; Wu J; Bao X; Honea N; Xie Y; Kim S; Sparreboom A; Sanai N
    Clin Cancer Res; 2017 Dec; 23(24):7454-7466. PubMed ID: 28928160
    [No Abstract]   [Full Text] [Related]  

  • 38. Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters.
    Tiwari AK; Sodani K; Wang SR; Kuang YH; Ashby CR; Chen X; Chen ZS
    Biochem Pharmacol; 2009 Jul; 78(2):153-61. PubMed ID: 19427995
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association between acquired resistance to PLX4032 (vemurafenib) and ATP-binding cassette transporter expression.
    Michaelis M; Rothweiler F; Nerreter T; van Rikxoort M; Zehner R; Dirks WG; Wiese M; Cinatl J
    BMC Res Notes; 2014 Oct; 7():710. PubMed ID: 25300205
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dual mTORC1 and mTORC2 inhibitor Palomid 529 penetrates the blood-brain barrier without restriction by ABCB1 and ABCG2.
    Lin F; Buil L; Sherris D; Beijnen JH; van Tellingen O
    Int J Cancer; 2013 Sep; 133(5):1222-33. PubMed ID: 23436212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.